Compare NBIX & VICR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | VICR |
|---|---|---|
| Founded | 1992 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.1B |
| IPO Year | 1996 | 1995 |
| Metric | NBIX | VICR |
|---|---|---|
| Price | $152.72 | $234.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 3 |
| Target Price | $180.91 | ★ $217.50 |
| AVG Volume (30 Days) | ★ 1.4M | 874.6K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.95 | ★ 1764.29 |
| EPS | ★ 3.30 | 0.44 |
| Revenue | $161,626,000.00 | ★ $452,701,000.00 |
| Revenue This Year | $24.73 | $37.01 |
| Revenue Next Year | $13.14 | $39.47 |
| P/E Ratio | ★ $45.72 | $520.84 |
| Revenue Growth | ★ 977.51 | 26.08 |
| 52 Week Low | $122.14 | $45.44 |
| 52 Week High | $186.12 | $382.65 |
| Indicator | NBIX | VICR |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 49.88 |
| Support Level | $125.85 | $134.89 |
| Resistance Level | $160.08 | $232.35 |
| Average True Range (ATR) | 6.42 | 13.78 |
| MACD | -2.47 | 5.38 |
| Stochastic Oscillator | 9.54 | 91.91 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others. The principal markets for the Company's power converters and systems are large original equipment manufacturers (OEMs), original design manufacturers (ODMs) and their contract manufacturers, and smaller, lower volume users, which are broadly distributed across several market areas.